EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieOpen Access

Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double-Blind, Randomized, Placebo-Controlled Study (LEGenD-1)

David G Armstrong iD, Michael S Conte iD, Joseph L Mills iD, Matthew T Menard iD, Dennis P Orgill iD, Robert D Galiano, Robert S Kirsner iD, Alik Farber iD, John C Lantis iD, Charles M Zelen iD, Marissa J Carter iD, Caitlin W Hicks iD und 1 weitere

Circulation: Cardiovascular Interventions · 2026

DOI: 10.1161/circinterventions.125.015648 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026. Verfasst von David G Armstrong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles (D.G.A.). Hauptthemen laut MEDLINE: Wound Healing, Genetic Therapy, Lower Extremity, Hepatocyte Growth Factor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: People with chronic limb-threatening ischemia lack Food and Drug Administration-approved therapies for wound healing, creating an unmet need for novel approaches. Prior studies of biologics in chronic limb-threatening ischemia have largely targeted end-stage patients with amputation-free survival as the primary outcome. This trial evaluated the efficacy of intramuscular administration of AMG0001, a plasmid encoding human HGF (hepatocyte growth factor), to promote ulcer healing in patients with chronic limb-threatening ischemia and neuroischemic ulcers. METHODS: LEGenD-1 was a double-blind, randomized, placebo-controlled phase II trial conducted at 22 US sites. Seventy-five participants with neuroischemic ulcers and toe pressure or transcutaneous oxygen pressure between 30 and 59 mm Hg were randomized to receive AMG0001 at 4 mg, 8 mg, or placebo. Injections were administered intramuscularly along an angiographically guided target artery path on days 0, 28, 56, and 84. The 2 coprimary end points were time to complete healing and the proportion of subjects with ulcers healed by 6 months in a pooled AMG0001 analysis. Secondary end points included healing by 12 months, ulcer recurrence, and hemodynamic changes. RESULTS: Baseline characteristics were comparable across groups (mean age 62.6 years; 80.0% male; 70.7% with diabetes). Mean toe pressure was 46.1 mm Hg, and transcutaneous oxygen pressure was 49.8 mm Hg. Median time to healing was significantly shorter with AMG0001 versus placebo (84 versus 280 days; P =0.007); 4 mg: 98 days ( P =0.017); 8 mg: 84 days ( P =0.022). By 6 months, 63.3% of AMG0001-treated participants healed versus 38.5% of placebo ( P =0.053). By 12 months, healing rates were 77.6% versus 46.2% ( P =0.010). Adverse events were similar across groups. CONCLUSIONS: Anatomically targeted intramuscular delivery of AMG0001 significantly accelerated healing in patients with moderate chronic limb-threatening ischemia and neuroischemic ulcers and may represent a promising nonsurgical therapeutic strategy. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04267640.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wound HealingGenetic TherapyLower ExtremityHepatocyte Growth FactorIschemiaLeg UlcerChronic Limb-Threatening IschemiaHumansDouble-Blind MethodMaleFemaleMiddle AgedAgedTreatment OutcomeTime FactorsInjections, IntramuscularUnited StatesChronic Disease

Stichwörter der Autor:innen

hemodynamicsoxygenplasmidsulcerwound healing

Substanzen

Hepatocyte Growth FactorHGF protein, human

Autor:innen und Institutionen

  • Department of Surgery, Keck School of Medicine of the University of Southern California, Los Angeles (D.G.A.).
  • Division of Vascular and Endovascular Surgery, University of California, San Francisco School of Medicine (M.S.C.).
  • Division of Vascular Surgery & Endovascular Therapy, Baylor College of Medicine, Houston, TX (J.L.M.).
  • Division of Vascular and Endovascular Surgery (M.T.M.), Brigham and Women's Hospital, Boston, MA.
  • Division of Plastic Surgery (D.P.O.), Brigham and Women's Hospital, Boston, MA.
  • Division of Plastic Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL (R.D.G.).

ORCID-Profile: David G Armstrong, Michael S Conte, Joseph L Mills, Matthew T Menard, Dennis P Orgill, Robert S Kirsner, Alik Farber, John C Lantis, Charles M Zelen, Marissa J Carter, Caitlin W Hicks

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Armstrong, D. G., Conte, M. S., Mills, J. L., Menard, M. T., Orgill, D. P., Galiano, R. D., Kirsner, R. S., Farber, A., Lantis, J. C., Zelen, C. M., Carter, M. J., Hicks, C. W., & Powell, R. J. (2026). Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double-Blind, Randomized, Placebo-Controlled Study (LEGenD-1). Circulation: Cardiovascular Interventions. https://doi.org/10.1161/circinterventions.125.015648

Vancouver

Armstrong DG, Conte MS, Mills JL, Menard MT, Orgill DP, Galiano RD, et al. Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double-Blind, Randomized, Placebo-Controlled Study (LEGenD-1). Circulation: Cardiovascular Interventions. 2026. doi:10.1161/circinterventions.125.015648

BibTeX
@article{Armstrong2026,
  author = {Armstrong, David G and Conte, Michael S and Mills, Joseph L and Menard, Matthew T and Orgill, Dennis P and Galiano, Robert D and Kirsner, Robert S and Farber, Alik and Lantis, John C and Zelen, Charles M and Carter, Marissa J and Hicks, Caitlin W and Powell, Richard J},
  title = {Anatomically Directed Lower Extremity Gene Therapy for Ulcer Healing: A Double-Blind, Randomized, Placebo-Controlled Study (LEGenD-1)},
  journal = {Circulation: Cardiovascular Interventions},
  year = {2026},
  doi = {10.1161/circinterventions.125.015648}
}
Kostenlos starten →